Physician profile
David Degrassi
NPI 1891465043
$3,377.04
in general payments reported to CMS, 2019-2025
24 companies · $1,633 in 2025
The $1,633 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $455 · 2024: $1,289 · 2025: $1,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,278 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,278.04 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $825.35 | 2023-2025 | Erleada, Akeega, Balversa |
| Dendreon Pharmaceuticals LLC | $507.19 | 2023-2025 | Provenge |
| Abbvie INC. | $334.98 | 2024-2025 | |
| Astellas Pharma US INC | $318.11 | 2024-2025 | Xtandi, Padcev |
| Sumitomo Pharma America, INC. | $200.02 | 2024-2025 | Gemtesa, Orgovyx |
| Ferring Pharmaceuticals INC. | $159.45 | 2025 | Adstiladrin |
| Olympus America INC. | $151.29 | 2023-2025 | Itind System |
| Teleflex LLC | $136.85 | 2023-2024 | Urolift |
| Bayer Healthcare Pharmaceuticals INC. | $132.91 | 2023-2025 | |
| Urogen Pharma, INC. | $109.14 | 2025 | |
| Tempus Ai, INC | $76.08 | 2024-2025 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $53.77 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $51.48 | 2023-2024 | Keytruda, Welireg, Lynparza |
| Endo USA, INC. | $47.73 | 2024 | Xiaflex |
| Endo Pharmaceuticals INC. | $45.67 | 2023-2024 | Xiaflex, Aveed |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $41.83 | 2024 | Axonics |
| Profound Medical Corp. | $41.55 | 2025 | Tulsa-Pro |
| Amgen INC. | $40.53 | 2023 | Xgeva |
| Avyxa Pharma, LLC | $24.73 | 2025 | |
| Laborie Medical Technologies Corp. | $19.59 | 2024 | Goby |
| Pfizer INC. | $16.49 | 2024 | |
| Immunitybio, INC. | $15.59 | 2025 | |
| Verity Pharmaceuticals INC. | $13.87 | 2025 | Tlando |
| Uc-Care (USA), INC | $12.84 | 2025 | Navigo Workstation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Degrassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.